메뉴 건너뛰기




Volumn 29, Issue 3, 2013, Pages 234-243

New anticoagulants as thromboprophylaxis after total hip or knee replacement

Author keywords

Anticoagulants; Arthroplasty; Economic evaluation; Health technology assessment; Venous thromboembolism

Indexed keywords

ANTICOAGULANTS; ECONOMIC EVALUATIONS; HEALTH TECHNOLOGY ASSESSMENTS; QUALITY OF DOCUMENTATIONS; STATISTICALLY SIGNIFICANT DIFFERENCE; TOTAL HIP REPLACEMENT (THR); TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 84880445469     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462313000251     Document Type: Article
Times cited : (12)

References (46)
  • 1
    • 0346994689 scopus 로고    scopus 로고
    • Duration of venous thromboembolism prophylaxis after surgery
    • Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124(Suppl):386S-392S.
    • (2003) Chest , vol.124 , Issue.SUPPL.
    • Kearon, C.1
  • 2
    • 77953667062 scopus 로고    scopus 로고
    • Venous thromboembolism after elective hip and knee replacemaent surgery
    • Haas S, LassenMR. Venous thromboembolism after elective hip and knee replacemaent surgery. EJHPP Pract. 2010;16:17-19.
    • (2010) EJHPP Pract , vol.16 , pp. 17-19
    • Haas, S.1    Lassen, M.R.2
  • 3
    • 84899469467 scopus 로고    scopus 로고
    • Dabigatran or Rivaroxaban Versus Other Anticoagulants for Thromboprophylaxis after Major Orthopedic Surgery: Systematic Review of Comparative Clinical-effectiveness and Safety
    • Ndegwa S, Moulton K, Arǵaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: Systematic review of comparative clinical-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
    • (2009) Ottawa: Canadian Agency for Drugs and Technologies in Health
    • Ndegwa, S.1    Moulton, K.2    Arǵaez, C.3
  • 4
    • 77952466576 scopus 로고    scopus 로고
    • Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
    • Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database Syst Rev (Online). 2010;4:CD005981.
    • (2010) Cochrane Database Syst Rev (Online) , vol.4
    • Salazar, C.A.1    Malaga, G.2    Malasquez, G.3
  • 5
    • 84880408536 scopus 로고    scopus 로고
    • Norwegian Medicine Agency accessed May 2011
    • Norwegian Medicine Agency. Preparatomtale. http://www.legemiddel verket.no/custom/Preparatsok/prepSearch-80333.aspx (accessed May 2011).
    • Preparatomtale
  • 8
    • 33644939196 scopus 로고    scopus 로고
    • Frequency and timing of clinical venous thromboembolism after major joint surgery
    • Bjornara BT,Gudmundsen TE, DahlOE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006;88:386-391.
    • (2006) J Bone Joint Surg Br , vol.88 , pp. 386-391
    • Bjornara, B.T.1    Gudmundsen, T.E.2    Dahlo, E.3
  • 9
    • 77956057713 scopus 로고    scopus 로고
    • A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
    • Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8:1966-1975.
    • (2010) J Thromb Haemost , vol.8 , pp. 1966-1975
    • Dahl, O.E.1    Quinlan, D.J.2    Bergqvist, D.3    Eikelboom, J.W.4
  • 10
    • 17544386944 scopus 로고    scopus 로고
    • The clinical course of deepvein thrombosis. Prospective long-term follow-up of 528 symptomatic patients
    • Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deepvein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423-428.
    • (1997) Haematologica , vol.82 , pp. 423-428
    • Prandoni, P.1    Villalta, S.2    Bagatella, P.3
  • 11
    • 0035344645 scopus 로고    scopus 로고
    • Trends in the incidence of venous stasis syndrome and venous ulcer: A 25-year population-based study
    • Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: A 25-year population-based study. J Vasc Surg. 2001;33:1022-1027.
    • (2001) J Vasc Surg , vol.33 , pp. 1022-1027
    • Heit, J.A.1    Rooke, T.W.2    Silverstein, M.D.3
  • 15
    • 84880404573 scopus 로고    scopus 로고
    • Omr°adeplan for rehabilitering. Sørlandet sykehus HF
    • Prosjektgruppe hofte-og kneopererte. Omr°adeplan for rehabilitering. Sørlandet sykehus HF; 2010.
    • (2010) Prosjektgruppe Hofte-og Kneopererte
  • 16
    • 84880443940 scopus 로고    scopus 로고
    • Norwegian Directorate of Health accessed 2011
    • Norwegian Directorate of Health. Innsatsstyrt finansiering 2010. http://helsedirektoratet.no/finansiering/isf/Sider/default.aspx (accessed 2011).
    • (2010) Innsatsstyrt Finansiering
  • 19
    • 14944386624 scopus 로고    scopus 로고
    • Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis
    • Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis. Am J Cardiovasc Drugs. 2005;5:121-130.
    • (2005) Am J Cardiovasc Drugs , vol.5 , pp. 121-130
    • Bjorvatn, A.1    Kristiansen, F.2
  • 20
    • 34147138285 scopus 로고    scopus 로고
    • Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs
    • R̈as̈anen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop. 2007;78:108-115.
    • (2007) Acta Orthop , vol.78 , pp. 108-115
    • R̈as̈anen, P.1    Paavolainen, P.2    Sintonen, H.3
  • 21
    • 7744231093 scopus 로고    scopus 로고
    • Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis
    • Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg. 2004;124: 507-517.
    • (2004) Arch Orthop Trauma Surg , vol.124 , pp. 507-517
    • Haentjens, P.1    De Groote, K.2    Annemans, L.3
  • 22
    • 0030638624 scopus 로고    scopus 로고
    • Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis
    • Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49-56.
    • (1997) J Am Med Inform Assoc , vol.4 , pp. 49-56
    • Lenert, L.A.1    Soetikno, R.M.2
  • 23
    • 0035669803 scopus 로고    scopus 로고
    • Representing uncertainty: The role of cost-effectiveness acceptability curves
    • Fenwick E, Claxton K, SculpherM. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
    • (2001) Health Econ , vol.10 , pp. 779-787
    • Fenwick, E.1    Claxton, K.2    Sculpher, M.3
  • 25
    • 17644409026 scopus 로고    scopus 로고
    • A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
    • Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111.
    • (2005) J Thromb Haemost , vol.3 , pp. 103-111
    • Eriksson, B.I.1    Dahl, O.E.2    Buller, H.R.3
  • 26
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • RE-MOBILIZE Writing Committee
    • RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
    • (2009) J Arthroplasty , vol.24 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2
  • 27
    • 35449007749 scopus 로고    scopus 로고
    • Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: TheRE-MODEL randomized trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: TheRE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
    • (2007) J Thromb Haemost , vol.5 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 28
    • 34548575058 scopus 로고    scopus 로고
    • Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.
    • (2007) Lancet , vol.370 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 29
    • 79953836474 scopus 로고    scopus 로고
    • Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721-729.
    • (2011) Thromb Haemost , vol.105 , pp. 721-729
    • Eriksson, B.I.1    Dahl, O.E.2    Huo, M.H.3
  • 30
    • 33644867218 scopus 로고    scopus 로고
    • Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    • Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-128.
    • (2006) J Thromb Haemost , vol.4 , pp. 121-128
    • Eriksson, B.I.1    Borris, L.2    Dahl, O.E.3
  • 31
    • 33751559902 scopus 로고    scopus 로고
    • A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    • Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.
    • (2006) Circulation , vol.114 , pp. 2374-2381
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3
  • 32
    • 45949103416 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    • Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
    • (2008) N Engl J Med , vol.358 , pp. 2776-2786
    • Lassen, M.R.1    Ageno, W.2    Borris, L.C.3
  • 33
    • 34250651947 scopus 로고    scopus 로고
    • Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement
    • Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685-693.
    • (2007) Thromb Res , vol.120 , pp. 685-693
    • Eriksson, B.I.1    Borris, L.C.2    Dahl, O.E.3
  • 34
    • 84886943075 scopus 로고    scopus 로고
    • Rivaroxaban for the prevention of venous thromboembolism: A single technology appraisal
    • Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: A single technology appraisal. Health Technol Assess. 2009;13(Suppl 3):43-48.
    • (2009) Health Technol Assess , vol.13 , Issue.SUPPL. 3 , pp. 43-48
    • Stevenson, M.1    Scope, A.2    Holmes, M.3    Rees, A.4    Kaltenthaler, E.5
  • 35
    • 65549169515 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
    • Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet. 2009;373:1673-1680.
    • (2009) Lancet , vol.373 , pp. 1673-1680
    • Turpie, A.G.1    Lassen, M.R.2    Davidson, B.L.3
  • 36
    • 46049106502 scopus 로고    scopus 로고
    • Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
    • Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
    • (2008) Lancet , vol.372 , pp. 31-39
    • Kakkar, A.K.1    Brenner, B.2    Dahl, O.E.3
  • 37
    • 0346688755 scopus 로고    scopus 로고
    • Relationship between deep venous thrombosis and the postthrombotic syndrome
    • Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164:17-26.
    • (2004) Arch Intern Med , vol.164 , pp. 17-26
    • Kahn, S.R.1    Ginsberg, J.S.2
  • 38
    • 0036861679 scopus 로고    scopus 로고
    • Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States
    • BottemanMF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24:1960-1986.
    • (2002) Clin Ther , vol.24 , pp. 1960-1986
    • Botteman, M.F.1    Caprini, J.2    Stephens, J.M.3
  • 39
    • 70349923899 scopus 로고    scopus 로고
    • A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting
    • McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics. 2009;27:829-846.
    • (2009) Pharmacoeconomics , vol.27 , pp. 829-846
    • McCullagh, L.1    Tilson, L.2    Walsh, C.3    Barry, M.4
  • 40
    • 60449095843 scopus 로고    scopus 로고
    • Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery
    • Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009;31:194-212.
    • (2009) Clin Ther , vol.31 , pp. 194-212
    • Wolowacz, S.E.1    Roskell, N.S.2    Maciver, F.3
  • 41
    • 84880444061 scopus 로고    scopus 로고
    • Verbalvedtak 4 vedr
    • ReportNo.: BU-sak 41/2009
    • Oslo kommune.Verbalvedtak 4 vedr. hjemmetjenesten. 2009. ReportNo.: BU-sak 41/2009.
    • (2009) Hjemmetjenesten
    • Kommune, O.1
  • 43
    • 4043081391 scopus 로고    scopus 로고
    • Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients
    • Offord R, Lloyd AC, Anderson P, Bearne A. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci. 2004;26:214-220.
    • (2004) Pharm World Sci , vol.26 , pp. 214-220
    • Offord, R.1    Lloyd, A.C.2    Anderson, P.3    Bearne, A.4
  • 44
    • 70350537133 scopus 로고    scopus 로고
    • Incidence and cost burden of post-thrombotic syndrome
    • Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28:465-476.
    • (2009) J Thromb Thrombolysis , vol.28 , pp. 465-476
    • Ashrani, A.A.1    Heit, J.A.2
  • 45
    • 45949099359 scopus 로고    scopus 로고
    • Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    • Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
    • (2008) N Engl J Med , vol.358 , pp. 2765-2775
    • Eriksson, B.I.1    Borris, L.C.2    Friedman, R.J.3
  • 46
    • 28444474155 scopus 로고    scopus 로고
    • BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
    • Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479-2486.
    • (2005) J Thromb Haemost , vol.3 , pp. 2479-2486
    • Turpie, A.G.1    Fisher, W.D.2    Bauer, K.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.